Sciensano
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 2018-01-01
- Employees
- 501
- Market Cap
- -
- Website
- https://www.sciensano.be
Clinical Trials
14
Active:2
Completed:8
Trial Phases
3 Phases
Phase 1:2
Phase 4:2
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Not Applicable
3 (42.9%)Phase 1
2 (28.6%)Phase 4
2 (28.6%)Telerehabilitation and Tele-psychological Support in Cancer Patients eCAN JA
Not Applicable
Recruiting
- Conditions
- Cancer
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Sciensano
- Target Recruit Count
- 354
- Registration Number
- NCT06007001
- Locations
- 🇧🇪
The Antwerp University Hospital (UZA), Antwerp, Belgium
🇨🇾German Oncology Center (GOC), Agios athanasios, Cyprus
🇨🇾CUT, Limassol, Cyprus
Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020)
Completed
- Conditions
- Severe Acute Respiratory InfectionInfluenza Viral InfectionsRespiratory Viral Infection
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Sciensano
- Target Recruit Count
- 12145
- Registration Number
- NCT05620953
COVID-19 Vaccination Uptake in Belgium : Sociodemographic and Socioeconomic Disparities
Completed
- Conditions
- COVID-19
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Sciensano
- Target Recruit Count
- 5341584
- Registration Number
- NCT05373420
- Locations
- 🇧🇪
Lisa Cavillot, Bruxelles, Belgium
Increase in Response by Offering Self-sampling Devices in Belgian GP Practices to Non-screened Women
Not Applicable
Recruiting
- Conditions
- Cervical Cancer
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Sciensano
- Target Recruit Count
- 1200
- Registration Number
- NCT04903561
- Locations
- 🇧🇪
Université catholique de Louvain, Brussels, Belgium
🇧🇪Université de Liège, Liège, Belgium
🇧🇪Maison médicale Neptune, Schaarbeek, Belgium
COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine
Phase 4
Completed
- Conditions
- Covid19
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Sciensano
- Target Recruit Count
- 145
- Registration Number
- NCT04852861
- Locations
- 🇧🇪
Mensura EDPB, Antwerp, Belgium
- Prev
- 1
- 2
- 3
- Next
News
No news found